Consequently, GLP-1 analogues such as liraglutide, exenatide, semaglutide, and lixisenatide, engineered to resist DPP-4 cleavage, are now utilized for managing T2DM [198,199]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.